• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Prevention of Dementia in Patients with Atrial Fibrillation
Korean Circ J. 2021 Apr;51(4):308-319. doi: 10.4070/kcj.2021.0027.ABSTRACTAtrial fibrillation (AF) is the most common form of arrhythmia in the elderly population and increases stroke risk by a factor of 4- to 5-fold. There is increasing evidence to suggest that incident AF may contribute to the development of dementia, independent of overt stroke. In particular, relatively younger patients with AF are more prone to dementia development than older patients with AF. Evidence is accumulating regarding the possible treatment strategies for preventing dementia in patients with AF. Oral anticoagulation may be effective for redu...
Source: Korean Circulation Journal - April 6, 2021 Category: Cardiology Authors: Daehoon Kim Pil Sung Yang Boyoung Joung Source Type: research

Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients.
Authors: Joung B Abstract Regulatory approvals of non-vitamin K antagonist oral anticoagulants (NOACs) have been based on large randomized phase III trials evaluating dabigatran, rivaroxaban, apixaban, or edoxaban relative to warfarin for atrial fibrillation (AF). The results of the trials showed that all NOACs were at least non-inferior to warfarin in the prevention of stroke/thromboembolism and showed lower rates of intracranial bleeding than those associated with warfarin. However, the trials were designed differently, varied in the inclusion/exclusion criteria, and used either one dose or a low/high dose of the...
Source: Korean Circulation Journal - November 26, 2017 Category: Cardiology Tags: Korean Circ J Source Type: research

Association of Gender With Clinical Outcomes in a Contemporary Cohort of Patients With Atrial Fibrillation Receiving Oral Anticoagulants
CONCLUSIONS: In contemporary anticoagulation for AF, SSE and major bleeding risks did not differ between sexes. However, women showed a lower risk of all-cause death rate than men, indicating that the use of oral anticoagulants for treating AF in females does not appear to be a risk factor for adverse clinical events.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02786095.PMID:35656931 | DOI:10.4070/kcj.2021.0399
Source: Korean Circulation Journal - June 3, 2022 Category: Cardiology Authors: Minjeong Kim Jun Kim Jin-Bae Kim Junbeom Park Jin-Kyu Park Ki-Woon Kang Jaemin Shim Eue-Keun Choi Young Soo Lee Hyung Wook Park Boyoung Joung Source Type: research

Pages: 1  2  3  4  5  6